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Transgenic RNAi, an alternative to the gene knockout approach, can induce hypomorphic phenotypes that re-
semble those of the gene knockout in mice. Conditional transgenic RNAi is an attractive choice of method for 
reverse genetics in vivo because it can achieve temporal and spatial silencing of targeted genes. Pol III promoters 
such as U6 are widely used to drive the expression of RNAi transgenes in animals. Tested in transgenic mice, a 
Cre-loxP inducible U6 promoter drove the broad expression of an shRNA against the Pink1 gene whose 
loss-of-functional mutations cause one form of familial Parkinson’s disease. The expression of the shRNA was 
tightly regulated and, when induced, silenced the Pink1 gene product by more than 95% in mouse brain. How-
ever, these mice did not develop dopaminergic neurodegeneration, suggesting that silencing of the Pink1 gene 
expression from embryo in mice is insufficient to cause similar biochemical or morphological changes that are 
observed in Parkinson’s disease. The results demonstrate that silencing of the PINK1 gene does not induce a re-
liable mouse model for Parkinson’s disease, but that technically the inducible U6 promoter is useful for condi-
tional RNAi in vivo. 
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1.  Introduction 
RNA interference (RNAi) is widely used to si-
lence gene expression in the study of gene functions 
and in the development of therapeutic strategies [1-3]. 
RNAi is induced by short double-stranded RNA called 
small interfering RNA (siRNA), of which one strand 
(guide strand) is incorporated into RNA-Induced Si-
lencing Complex (RISC) and directs localization and 
degradation of targeted RNA molecules with com-
plementary sequence to the siRNA guide strand [4-6]. 
Sustained RNAi can be achieved by introducing a 
gene-based construct that synthesizes short hairpin 
RNA (shRNA) from either RNA polymerase II or III 
(Pol II or III) promoters [2, 3]. Pol III promoters such as 
U6 or H1 offer advantages over Pol II promoters, be-
cause the compact sequence of Pol III promoters is 
easier to handle and their ubiquitous expression pat-
tern allows for broad silencing of a target gene [7-9]. 
An shRNA transcript synthesized from a Pol III pro-
moter is exported by Exportin-5 to the cytoplasm 
where it is processed by Dicer to form siRNA [10, 11], 
the final and functional product of shRNA. If an 
shRNA-expressing construct is integrated into the ge-
nome, it becomes a sustainable source of siRNA and 
produces sustained RNAi effects, an approach that is 
called transgenic RNAi. This approach has been 
demonstrated to successfully reproduce phenotypes of 
the gene knockouts [12-14]. 
Transgenic RNAi is a convenient alternative to 
the gene knockout approach for the following reasons: 
it can avoid the use of embryonic stem cells; it enables 
the generation of varying degrees of hypomorphic 
phenotypes because RNAi-mediated silencing is 
d o s e - d e p e n d e n t  o f  s i R N A ;  a n d  i t  c a n  b e  a p p l i e d  t o  
mammalian species other than mice (such as rats) in 
which gene knockout has not yet been established [3, 
12]. When a constitutive promoter is used to drive 
shRNA expression, the dominant nature of RNAi lim-
its its use to target some critical genes whose loss re-
sults in premature death or infertility. To overcome 
this drawback, a variety of inducible promoters such 
as Cre-loxP-regulated U6 have been created and tested 
in transgenic studies [13, 15, 16]. Several strategies are Int. J. Biol. Sci. 2007, 3 
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available to create 
Cre-LoxP-regulated U6 promoters: 
the first is to place the loxP site 
between the distal sequence ele-
ment (DSE) and the proximal se-
quence element (PSE) of the pro-
moter [13, 16]; the second is to use 
the loxP site as a loop within the 
shRNA structure [17]; and the third 
is to modify the TATA box of the 
promoter to introduce a mutant 
loxP site [15, 18]. Our previous 
studies tested the first strategy and 
found a leakage of the promoter in 
transgenic mice [16]. The second 
strategy compromises the effi-
ciency of shRNA processing be-
cause the shRNA is added with an 
excessive length of the loop se-
quence [19]. The third strategy has 
been developed independently by 
different groups [15, 18], and was 
reported to tightly regulate shRNA 
expression in cell culture and in 
mouse embryos. Here we tested 
the third strategy in adult mice in 
which the PTEN-induced putative 
kinase 1 (PINK1) gene, a Parkinson 
disease (PD)-associated gene, was 
targeted. 
Most PD cases are sporadic, 
but some rare forms are caused by 
mutations in individual genes. 
PINK1 is a mitochondrial protein 
which is thought to cause PD by 
loss-of-functional mutations and 
whose depletion leads to mito-
chondrial dysfunction in droso-
phila [20, 21]. PINK1 knockout 
mice have not been reported. Using transgenic RNAi 
approach, we generated conditional PINK1-silenced 
mice. In these transgenic mice, the expression of the 
PINK1 shRNA was tightly regulated by the Cre-loxP 
system and activation of the RNAi transgene resulted 
in silenced expression of the Pink1  gene in various 
tissues and to less than 5% of the normal levels in the 
central nerve system. Silencing of the PINK1 gene ex-
pression did not cause a loss of the dopaminergic 
neurons in the PINK1 RNAi transgenic mice. 
2.  Materials and Methods 
Plasmid construction 
The coding sequence of the mouse PINK1 gene 
was copied by PCR from a cDNA pool that was re-
verse-transcribed from the cellular RNA of mouse 
brain. The PINK1 open reading frame (ORF) was 
cloned downstream of the ORF of enhanced green 
fluorescence protein (EGFP; Figure 1A) in the vector 
pEGFP-N1 (Clonetech). 
 
Figure 1. Screening for effective shRNA against the mouse 
Pink1 gene. (A) A mouse Pink1 gene was inserted at the 
C-terminal and in the frame of the EGFP gene that was 
driven by the CMV promoter; the fusion protein served as an 
indicator for the RNAi-mediated knockdown of Pink1 gene 
expression. (B) The native mouse U6 promoter was used to 
drive the expression of PINK1-shRNA gene that consisted of 
an shRNA sense strand, the loop sequence TTCAAGAGA, 
and an shRNA antisense strand. (C) The shRNA targeting 
sequences on mouse PINK1 mRNA were shown when the 
translation start-site was set at 1. (D) The fluorescent inten-
sity of GFP protein was measured in the lysate of cells that 
were transfected with a combination of EGFP-PINK1 ex-
pression vector (A) with either the PINK1-shRNA or an 
shRNA-control vector that does not target any gene. 
 
U6-shRNA vectors were constructed as described 
earlier [16, 22]. Briefly, single-stranded DNA oligonu-
cleotides were chemically synthesized and annealed to 
form double-stranded DNA that consisted of shRNA 
sense sequence, the loop sequence TTCAAGAGA, 
shRNA antisense sequence, and a string of six 
thymidine residues which served as transcrip-Int. J. Biol. Sci. 2007, 3 
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tion-terminating signal for 
RNA polymerase III promoters. 
The double-stranded DNA 
oligonucleotide flanked with 
restriction sites was cloned 
downstream of mouse U6 
promoter in an expression 
vector. For conditional expres-
sion of shRNA, a 
Cre-loxP-inducible U6 pro-
moter was generated by a 
similar strategy which mutated 
the sequence around TATA 
box of the U6 promoter to cre-
ate a mutant loxP site [15, 18]. 
The U6 promoter was reversi-
bly inactivated after a stuffer 
sequence of 1kb was inserted 
between the two mutant loxP 
sites (Figure 2A), but to be re-
covered by Cre-mediated exci-
sion of the stuffer sequence [23] 
(Figure 2B). The stuffer se-
quence contained multiple 
strings of thymidine along with 
the neomycin gene ORF and 
the SV40 poly (A) signal. All 
the plasmids were se-
quence-verified. 
 
Figure 2. Conditional expression 
of PINK1-shRNA silenced PINK1 
gene expression in the transgenic 
mice. (A) PINK1-RNAi transgenic 
mice were generated by pronuclear 
injection of a PINK1-shRNA con-
struct under control of a 
Cre-loxP-inducible mouse U6 
promoter that was temporally in-
activated by insertion of a 
LoxP-flanked stuffer sequence at 
its TATA box. (B) After 
Cre-mediated excision of the 
stuffer sequence from the promoter 
region, the integrity of the U6 
promoter was recovered in the 
double transgenic mice that carried 
both the Cre and PINK1-RNAi 
transgenes. (C) The RNAi transgene-positive founders were identified by PCR amplification of a fragment of the transgene 
DNA extracted from mouse tail. Positive control (C+): PCR amplification of the transgene construct; negative control (C-): 
PCR amplification of genomic DNA extracted from wildtype mouse tail. (D) The expression of the PINK1-RNAi transgene in 
mouse tissues (FB, forebrain; BS, brainstem) was measured with Northern blotting in the presence of an RNA probe com-
plementary to the antisense strand of the PINK1-RNAi transgene. Each lane was loaded with 20µg of total cellular RNA that 
was extracted from the tissues of the Cre and PINK1-RNAi double transgenic (RNAi+/Cre+) or the PINK1-RNAi single 
transgenic mice (RNAi+/Cre-). Equal loading was controlled by probing the upper part of the same membrane with a mouse 
U6 RNA-specific probe. (E) The expression of PINK1 mRNA was examined with quantitative PCR, and the level of PINK1 
mRNA was calculated relative to that of the housekeeping gene L17. The degrees of RNAi-mediated knockdown were ex-
pressed as a ratio of the relative level of PINK1 mRNA in the RNAi-transgenic tissue to that in non-transgenic tissue in which 
the relative level of PINK1 mRNA was set to 1 (control). Abbreviations are FB for forebrain, BS for brainstem, and KD for 
kidney. (F) Western blot measured the level of PINK1 protein in mitochondrial extract from mouse brain. Equal loading was 
examined by probing the same membrane with an antibody against the mitochondrial protein SOD2. 
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Cell culture and transfection 
HEK293 cells were grown in DMEM medium 
supplemented with 10% fetal bovine serum (FBS), 100 
units/ml penicillin, and 100µg/ml streptomycin. The 
day before transfection, the cells (70-90% of confluence) 
were detached by trypsin treatment, plated onto 6-well 
plates, and cultured in 10% FBS-containing medium 
without antibiotics. In the absence of serum, the cells 
were transfected with the transfection reagent lipofec-
tamine-2000 (Invitrogen) per manufacturer’s instruc-
tion. FBS (10%) and antibiotics were added four hours 
after transfection. The growth medium was changed 
every 24 hours. 
Fluorescence measurement 
Cells were harvested by centrifugation and 
snap-frozen in liquid nitrogen at 28 hours after trans-
fection. The cell pellet was lyzed in ice-cold reporter 
buffer (Promega) that was supplemented with prote-
ase inhibitors (complete, EDTA-free, 1 tablet/10 ml 
buffer; Roche). The lysate was cleared by centrifuga-
tion (14000 rpm) at 4°C for 10 minutes. Total protein in 
the supernatant was measured by BCA assay (Pierce; 
Rockville IL). Protein concentration of each sample 
was adjusted to 0.5 mg/ml with the reporter buffer. 
Fluorescence of green fluorescence protein (GFP) in 
140 µl of samples was measured by fluorescence spec-
troscopy (Photon Technology International) with ex-
citation at 460 nm and recording from 485 to 565 nm. 
The spectrum peak detected at 505 nm represented the 
fluorescence intensity of GFP. Fluorescence in un-
transfected lysate was measured as background and 
subtracted from measurements of the transfected lys-
ate [22, 24]. 
Generation of RNAi transgenic mice 
A PINK1-shRNA construct of 2.2kb was lin-
earized by restriction digestion and purified from 
agarose gel (Figure 2A). The RNAi transgenic mice 
were generated by pronuclear injection of the trans-
gene construct into fertilized eggs that were produced 
from the crossing of C57BL/6 with SJL mice. Trans-
gene-positive founder and offspring were identified by 
PCR-magnification of a part of the transgene, a part 
which was across the promoter region and the stuffer 
sequence (forward primer: 
5’-AGACTTGTGGGAGAAGCTCG-3’; reverse primer: 
5’-GCCTCTTCATCGGGAATGC-3’). The promoter 
activity was recovered after Cre-mediated excision of 
the stuffer sequence, and the RNAi transgene was thus 
expressed. The RNAi-active mice that carried both the 
Cre and PINK1-shRNA transgenes were identified by 
PCR-magnification of a part of the RNAi transgene, a 
part that consisted of the promoter sequence and the 
sense sequence of the shRNA (forward primer: 
5’-AGCCGATTGTCTGTTGTGC-3’; reverse primer: 5’- 
CTTCTGTAAGTAACTGCTCC-3’). The PINK1-RNAi 
active mice were backcrossed to FVB genomic back-
ground for at least five generations before they were 
used for experiments. Animal usage followed the NIH 
guideline and the protocol was approved by the In-
stitutional Animal Care and Use Committees (IACUC) 
of the authors’ institutions. 
Northern blot 
Mice were decapitated under deep anesthesia 
and their tissues were quickly dissected, snap-frozen 
in liquid nitrogen, and stored at -80°C. Total cellular 
RNA was extracted from the frozen tissues with the 
reagent Trizol (Sigma). RNA samples (20 µg each) 
were separated on 12% polyacrylamide gels and 
transferred onto Hybond TM-N+ membranes (Amer-
sham). After UV cross-linking, the membrane was cut 
into two parts: the low part was probed with an RNA 
probe complementary to the antisense strand of the 
mouse PINK1 shRNA; the upper part was probed with 
an RNA probe complementary to a part of mouse U6 
RNA (the sequence of U6 RNA probe: 
5’-TTCACGAATTTGCGTGTCATCCTTGCG-3’). RNA 
probes were synthesized by in vitro transcription with 
T7 RNA polymerase and labeled by addition of Di-
goxigenin-11-uridine-5'-triphosphate instead of 
uridine-5'-triphosphate during RNA synthesis (RNA 
probe synthesis kit: Roche). After probing with specific 
RNA probes, the membranes were incubated with 
anti-Digoxigenin-AP antibodies (Roche), and the sig-
nals were detected with CDP-star kit and documented 
on a Kodak Image Station. 
Quantitative PCR 
For determination of mRNA levels, total RNA 
isolated with Trizol reagent was further purified with 
RNA easy kit and digested on column with RNase-free 
DNase (Qiagen). One microgram of purified total RNA 
from each sample was reversely transcribed to cDNA 
with oligo-dT primer (RT kit, Invitrogen), and the re-
sulting cDNA was measured by quantitative PCR with 
SYBR green kit per manufacturer’s instruction 
(Qiagen). For quantitative PCR, the following primers 
were used at a concentration of 500nM: mouse PINK1 
primers GCTTGCCAATCCCTTCTATG (forward) and 
CTCTCGCTGGAGCAGTGAC (reverse); OAS1 prim-
ers CGTGCTGCCAGCCTATGATTT (forward) and 
TTGGTTGGGCGACAGTTCAG (reverse); STAT1 
primers GCTGGGCGTCTATCCTGTGGT (forward) 
and GCTCAGCTGGTCTGCGTTCA (reverse); and 
mouse L17 primers CGGTATAATGGTGGAGTTG 
(forward) and ACCCTTAAGTTCAGCGTTACT (re-
verse). Cycling conditions were 15 min at 95°C fol-
lowed by 40 cycles of 15 seconds at 94°C, 30 seconds at 
60°C, and 20 seconds at 72°C. Aliquots of the amplified 
products were separated on 3% agarose gels to ensure 
amplification of the specific products at the predicted 
length. The threshold cycle number (Ct) for an exam-
ined gene was normalized to the Ct for the house-
keeping gene, namely ribosomal RNA L17. The rela-
tive mRNA level of the gene of interest was deter-
mined and expressed as a ratio of the mRNA level in 
the transgenic mouse tissue to that in the wildtype 
mouse tissues as described previously [16]. 
Since the PINK1 RNAi transgene is driven by 
mouse U6 promoter, the copy number of the RNAi 
transgene can be estimated by determination of the Int. J. Biol. Sci. 2007, 3 
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total copies of mouse U6 promoters in the endogenous 
U6 gene and in the PINK1 RNAi transgenes. The 
number of copies of the PINK1 RNAi transgenes was 
estimated by real-time PCR analysis of mouse tail 
DNA. The primers for the real-time PCR were de-
signed for magnification of mouse U6 promoter: 
TCCGACGCCGCCATCTCTA (forward) and 
TATCGCACATTAAGCCTCTA (reverse). The Ct of 
the U6 promoter was normalized to the internal con-
trol glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), which was amplified using primers 
CCACTCTTCCACCTTCGATG (forward) and 
TCCACCACCCTGTTGCTGTA (reverse). The copy 
number of the PINK1 RNAi transgene was calculated 
relative to the endogenous mouse U6 gene which is 
known two copies per genome [16]. 
Western blot  
Mice were decapitated under deep anesthesia 
and their brains were dissected. Mouse brains were 
minced in a buffer (pH 7.4) that consisted of 10 mM 
Tris-HCl, 0.5 mM EDTA, 0.25 M sucrose, and a mix-
ture of protease inhibitors (Sigma). The minced tissue 
was further homogenized with Dounce homogenizers 
for 20 strokes each with pestle A (clearance 0.12 mm) 
and pestle B (clearance 0.06 mm). Tissue debris, un-
broken cells, and cell nuclei were removed by cen-
trifugation at 1000 x g for 20 minutes; the supernatant 
was centrifuged at 16,000 g for 20 minutes to pellet 
gross mitochondria as described previously [25]. The 
mitochondrial pellets were homogenized in ice-cold 
lysis buffer that consisted of 0.4% NP-40, 0.2 mM 
Na3VO4, 20 mM HEPS (pH 7.9), and a cocktail of pro-
tease inhibitors (Sigma). Mitochondrial lysates were 
cleared by centrifugation, and protein content in the 
cleared lysate was determined by BCA assay. Equal 
amounts of protein were resolved on precast 4-20% 
gradient SDS-PAGE and blotted onto GeneScreen Plus 
membrane (Perkin Elmer). PINK1 protein was de-
tected by incubation of the membrane with a rabbit 
anti-PINK1 antibody (Cayman Chemical: #10006283) 
and by signal development with Super Signal kit 
(Pierce). After detection of PINK1 protein, the mem-
brane was stripped in an SDS buffer (2% SDS, 100 mM 
ß-mercaptoethanol, 62.5 mM Tris-HCl, pH 6.7) at 55 
°C for 30 minutes and used for detecting 
immunoreactivity of the mitochondrial protein SOD2, 
which served as a loading control [14]. 
Immunostaining and cell counting 
Mice were decapitated and their brains were re-
moved and cut into two parts: the front section was 
used for dissection of the striatum over ice and the 
back section was submersion-fixed in 4% paraformal-
dehyde in 0.1 M phosphate-buffered saline at 4°C. Af-
ter fixation in 4% paraformaldehyde for 2 days, mouse 
brains were dehydrated in 30% sucrose and then cut 
into serial coronal sections (40 μm thick) on a Cryostat. 
Every third section through the entire midbrain was 
incubated with a rabbit antibody against tyrosine hy-
droxylase (TH; 1:1000; Pel-Freez), an enzyme that 
catalyzes the rate-limiting step in dopamine synthesis 
and is a reliable marker for viable dopaminergic neu-
rons. After thorough washes, tissue sections were se-
quentially incubated with biotinylated goat anti-rabbit 
IgG (1:500; Vector Laboratories), and thereafter with 
peroxidase-conjugated avidin-biotin complex (ABC kit; 
Vector Laboratories). Bound antibodies were visual-
ized by addition of diaminobenzidine (Vector Labo-
ratories), and tissue sections were mounted in sequen-
tial order (rostral to caudal), dried and covered. The 
total number of TH-positive neurons in the substantia 
nigra pars compact (SNc) was estimated by stereo-
logical counting with a fractionator-based unbiased 
assay, as described earlier [26]. Therefore, the number 
of TH-positive neurons was independent of their size, 
shape or orientation; tissue shrinkage; or anatomical 
level. 
HPLC measurement 
Dissected mouse striata were homogenized in 
0.1M perchloric acid by sonication at 4°C. Tissue lys-
ate was cleared by centrifugation at 4°C, and the 
supernatant was collected for measurement of 
dopamine and its metabolites by electrochemical 
detection using high performance liquid 
chromatography as described [27]. 
Behavior test 
Mouse motor function was evaluated with an 
accelerating rotarod as described [16]. Mice were 
trained to stay on a rotating rotarod two days before 
performing the motor function test which was done 
monthly. Each animal was tested for 3 trials each time 
and the longest time that the mouse stayed on the ro-
tating rod was used for analysis of motor function. 
Statistical analysis 
Data were expressed as means ± SEM values. The 
statistical significance was tested with ANOVA fol-
lowed by Tukey’s post hoc test to compare group 
means. In all analyses, the null hypothesis was re-
jected at a level of 0.05. 
3.  Results 
Selection of effective PINK1-shRNA 
RNAi-mediated inhibition is dose-dependent of 
the RNAi trigger siRNA, but the maximal inhibition 
depends on the potency of the RNAi trigger [14, 28]. 
Besides its gene-specific inhibition, RNAi may also 
cause side-effects or toxicities which are dependent on 
sequence and dose of siRNA or shRNA used [29-31]. 
To achieve maximal RNAi in vivo without unexpected 
effects, a potent shRNA should be selected and used 
for pronuclear injection. Five shRNA-targeting se-
quences were chosen from the coding sequence of 
mouse  Pink1 gene, and the RNAi efficacy of each 
shRNA was tested in HEK293 cells. After cotransfec-
tion with the GFP-tagged Pink1 mini-gene, the inten-
sity of GFP fluorescence was determined and used as 
an indicator for target gene expression. Although a 
control shRNA (sense sequence: CCA-
GACTTAGCTGCTGTATCGGCT) which did not tar-
get any gene failed to induce any inhibition, all five Int. J. Biol. Sci. 2007, 3 
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PINK1-shRNA silenced their 
target gene expression by dif-
ferent degrees from 50% to 85%, 
indicating that the RNAi effect 
was sequence-dependent of the 
PINK1-shRNA (Figure 1). These 
two shRNAs, #2 and #5, gave 
the best inhibition when the 
shRNA was used at a low ratio 
to its target by 1:2. In transient 
transfection, an shRNA that is 
able to inhibit its target expres-
sion by 80% can be defined ef-
fective [14, 22]. Thereby, we 
chose PINK1-shRNA-5 for the 
subsequent transgenic study. 
 
Figure 3. Silencing of the PINK1 
gene expression does not cause 
dopaminergic neuron death. (A) The 
striatal contents of the neurotrans-
mitter dopamine (DA) and its me-
tabolites DOPAC and HVA were 
measured with HPLC in the tissues 
of the RNAi-activated mice (RNAi) 
or its wildtype littermate (WT) at 
age of 6 months. Representative 
photos of midbrain section immu-
nostained for TH were taken from 
the wildtype (B) or the 
PINK1-RNAi active mice (C). Ar-
rows point to substantia nigra pars 
compacta (SNc). (D) The total 
number of TH-positive neurons in 
the SNc was counted stereologically. 
(E) Mouse motor activity was 
measured on rotating rod. Abbre-
viations are WT for wildtype and 
RNAi for RNAi-transgenic mice. 
Data are mean ± SEM (n = 4-6). 
Expression of PINK1 shRNA 
from a Cre-loxP-inducible U6 
promoter was tightly regulated 
For conditional RNAi, the effective 
PINK1-shRNA was expressed from a Cre-loxP induc-
ible U6 promoter which was reversibly inactivated by 
insertion of a loxP-flanked stuffer sequence at the 
TATA box [15, 18]. By pronuclear injection, 54 trans-
genic founders were generated and nine were identi-
fied transgene-positive (Figure 2C). Five positive lines 
gave offspring that carried the RNAi transgene in 
germline (data not shown). None of the RNAi trans-
genic mice expressed the transgene before they were 
mated with a Cre-transgenic mouse, indicating no de-
tectable leakage of the Cre-loxP-regulatable U6 pro-
moter. U6 promoter activity was expected to be re-
stored in the double transgenic mice that were gener-
ated by the crossing of PINK1-RNAi transgenic mice 
with CMV-Cre transgenic mice because the Cre en-
zyme would mediate excision of the stuffer sequence 
and recover the U6 promoter activity. Non-excision or 
incomplete excision was identified by PCR-detection 
of the stuffer sequence; whereas, complete excision 
was identified by a lack of the stuffer sequence and a 
recovery of the distance between the U6 promoter and 
the shRNA upon PCR detection. Cre-mediated exci-
sion was complete in every line except line #35, which 
displayed incomplete excision of the stuffer sequence 
by Cre activity (data not shown). Nevertheless, the 
product of RNAi transgene was detected in different 
tissues of the double transgenic mice from line #35 as 
well as line #8. The CMV-Cre transgenic mice express 
Cre recombinase ubiquitously [32], and thus, the 
PINK1 RNAi transgene can be activated in every tis-
sue. RNAi transgene product was detected by North-
ern blot in all tissues (Figure 2D, E). Line #8 expressed 
the RNAi transgene at a higher level than line #35 and 
was used for further experiments. No leakage in 
shRNA expression was detected before Cre induction 
(Figure 2D). By quantitative PCR, we measured the 
copy number of the PINK1 RNAi transgenes for these Int. J. Biol. Sci. 2007, 3 
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two expressing lines: #8 and #35. Initially, the line-8 
carries 3 copies of the quiescent PINK1 RNAi trans-
gene and the line-35 carries 4 copies of the transgene. 
After crossing with the CMV-Cre transgenic mice, the 
PINK1 RNAi transgene was activated by 
Cre-mediated excision of the intervening sequence 
from the promoter region. In the Cre and 
PINK1-RNAi double transgenic mice, the copy num-
ber was reduced to one copy for the line-8, but to 2 
copies for the line-35. 
Conditional RNAi silenced Pink1 gene expression 
but did not cause dopaminergic death 
Broad expression of PINK1 shRNA resulted in a 
significant knockdown of the PINK1 mRNA in the 
central nervous system, heart, liver, kidney, muscle, 
spleen, and testis (Figure 2E). The level of the PINK1 
mRNA was reduced to the detection limit by PCR in 
mouse brainstem where dopaminergic neurons reside, 
and the level of PINK1 protein was below detection 
threshold of Western blot in the mitochondrial pro-
teins from mouse brain (Figure 2F). 
Both PINK1 RNAi-inactive (before Cre-mediated 
excision) and RNAi-active (after Cre-mediated exci-
sion) mice did not present gross abnormalities. PINK1 
is associated with familial Parkinson’s disease that is 
characterized by progressive degeneration of the 
dopaminergic neurons in SNc and the dopaminergic 
terminals in the striatum. To determine whether these 
characteristics were recapitulated in PINK1-silenced 
mice, we examined the TH-positive neurons in the 
SNc. No difference in cell and tissue structure was 
detected (Figure 3B, C). Stereological counting of the 
TH-positive neurons in the SNc did not reveal a sig-
nificant difference between the wild type and the 
PINK1-silenced mice at age of 6 months (Figure 3D) or 
1 year (data not shown). Measurements of dopamine 
and its metabolites showed a trend – though not sta-
tistically significant – for increased concentrations in 
the striatum (Fig. 3A). Consistent with the normal 
level of striatal dopamine, the motor function of 
PINK1-silenced mice was also normal when tested on 
a rotorod (Figure 3E). 
Long-term expression of PINK1 shRNA did not 
cause dsRNA-dependent interferon response 
In mammals, expression of shRNA may cause 
dsRNA-dependent interferon response which is de-
pendent on the sequence length and content of shRNA 
[29-31]. An shRNA longer than 30 nucleotides may 
activate interferon pathways; whereas, a shorter one 
may not. The commonly used shRNA of 21-27 nucleo-
tides can avoid interferon response in most situations; 
however, some short shRNA can still stimulate the 
interferon signaling pathway [29-31]. The results of 
gene silencing may be complicated by potential inter-
feron response. To exclude this possibility, we exam-
ined the expression of oligoadenylate synthetase 1 
(OSA1) and signal transducer and activator of tran-
scription 1 (STAT1), which are known to be induced 
by some shRNA [29-31]. Real-time PCR analysis failed 
to detect an upregulation of the OSA1 and STAT1 
genes in the brain and spleen tissues of PINK1 RNAi 
transgenic mice (Figure 4), indicating that expression 
of the PINK1 shRNA transgene did not induce sig-
nificant interferon response. 
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Figure 4. Expression of the PINK1-RNAi transgene did not 
upregulate the expression of OSA1 and STAT1 genes in the 
transgenic mice. Levels of the mRNA for each gene were 
determined by quantitative PCR. The levels of OAS1 and 
STAT1 mRNA were normalized to that of GAPDH mRNA, 
and the relative mRNA level in the RNAi-transgenic tissues 
was expressed as a ratio to that in wildtype tissues. Data are 
mean ± SEM (n = 4). 
4.  Discussion 
We tested a Cre-loxP-regulatable U6 promoter in 
RNAi transgenic mice. The results showed that this 
promoter is fully regulatable in that it was completely 
inactive before induction, but upon Cre induction, it 
drove the expression of the shRNA ubiquitously. Si-
lencing of the Pink1 gene expression did not induce 
Parkinson’s disease phenotypes, including a loss of 
the dopaminergic neurons in the SNc and the neuro-
transmitter dopamine in the striatum. 
Transgenic RNAi is an attractive approach for 
reverse genetics in mice because it has certain advan-
tages. It is faster and cheaper as compared with gene 
knockout approach by homologous recombination. It 
can be applied virtually in all mammalian species as 
exemplified by its capability of silencing genes in mice, 
rats and goat [12-14, 33-36]. Inducible RNAi based on 
the Cre-loxP system has also been developed in 
transgenic mice, and it enables the investigator to con-
trol gene silencing spatially and temporally [13, 16, 37]. 
One design of Cre-loxP inducible U6 promoter is to 
increase the distance between DSE and PSE elements 
of the promoter [16]. A shortcoming of this design is a 
certain level of leakage expression of shRNA before 
Cre induction. This is not surprising because even a 
DSE-deleted U6 promoter still has some promoter ac-
tivity [38, 39]. By using a modified loxP sequence that 
contains a TATA box and by insertion of a stuffer se-
quence between PSE and TATA box, the expression of 
shRNA by the modified U6 promoter is interrupted 
[38, 39]. Previous studies have shown an absence of 
shRNA synthesis in oocytes and T cells for the regu-
lated promoter [38, 39]. We applied this U6 promoter 
to drive the PINK1 RNAi transgene and demonstrate 
the absence of any leakage of the transgene expression 
in all tissues of the transgenic mice and a functional 
recovery of the promoter upon Cre induction. Thus, 
this Cre-loxP regulated U6 promoter is reliable for 
reverse genetics in vivo. Int. J. Biol. Sci. 2007, 3 
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Transgenic RNAi has been demonstrated capable 
of silencing gene expression in transgenic mice and 
inducing phenotypes of the gene knockout. In trans-
genic mice, an shRNA against Id4 gene induces de-
velopmental defects in kidney [12]; silencing of Fgfr2 
gene causes embryonic lethality [13]; inhibition of 
Msy2 gene expression in oocytes results in reduced 
fertility [33]; and silencing of Sod2 gene by transgenic 
RNAi leads to SOD2 dysfunction that results in severe 
consequences resembling the phenotypes of Sod2 gene 
knockout [14]. Transgenic RNAi can recapitulate gene 
knockout phenotypes by RNAi-mediated continuous 
degradation of targeted gene product, namely, mRNA. 
In the PINK1 RNAi transgenic mice, the level of 
PINK1 mRNA was less than 5% of the mRNA in 
wildtype littermates. Drastic degradation of PINK1 
mRNA led to invisibility of PINK1 protein on Western 
blot. However, silencing of PINK1 gene did not induce 
dopaminergic death. This may not be surprising be-
cause knockout of two other Parkinson’s dis-
ease-linked genes, Parkin and DJ-1, fails to reproduce 
Parkinson’s disease phenotypes in mice [40-42]. Dele-
tion of either the Parkin or DJ-1 genes by gene knock-
out approach does not cause dopaminergic neuron 
death [43-49]. Silencing of the PINK1 gene is insuffi-
cient to induce dopaminergic death in mice, though 
deletion of the PINK1 gene causes severe phenotypes 
in Drosophila [20, 21]. This could be interpreted as a 
difference in animal species. Similarly, deletion of the 
Parkin gene in Drosophila causes severe phenotypes 
resembling the PINK1 knockout fly [50], but no loss of 
dopaminergic neurons is observed in Parkin knockout 
mice [44, 46]. Our results suggest that a lack of PINK1 
gene function is insufficient to cause dopaminergic 
neuron death in mice and indicate that this version of 
Cre-loxP regulated U6 promoter is reliable for condi-
tional gene silencing in vivo. 
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